Biricodar dicitrate

CAS No. 174254-13-8

Biricodar dicitrate( —— )

Catalog No. M35987 CAS No. 174254-13-8

Biricodar dicitrate (VX-710) is a potent MDR inhibitor with no anticancer activity and can be used to study prostate cancer.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 1112 In Stock
25MG 1824 In Stock
50MG 2213 In Stock
100MG 2883 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Biricodar dicitrate
  • Note
    Research use only, not for human use.
  • Brief Description
    Biricodar dicitrate (VX-710) is a potent MDR inhibitor with no anticancer activity and can be used to study prostate cancer.
  • Description
    Biricodar dicitrate (VX-710) is a potent MDR inhibitor with no anticancer activity and can be used to study prostate cancer.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Cell Cycle/DNA Damage
  • Target
    AChR
  • Recptor
    AChR | NF-κB
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    174254-13-8
  • Formula Weight
    987.95
  • Molecular Formula
    C46H57N3O21
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    OC(CC(C(O)=O)(O)CC(O)=O)=O.O=C(C1=CC(OC)=C(C(OC)=C1)OC)C(N2[C@@H](CCCC2)C(OC(CCCC3=CN=CC=C3)CCCC4=CN=CC=C4)=O)=O.OC(CC(C(O)=O)(O)CC(O)=O)=O
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

molnova catalog
related products
  • YM-58790

    YM-58790 free base is a potent mAChR antagonist that inhibits M1 mAChR, M2 mAChR, and M3 mAChR with Ki values of 28 nM, 260 nM, and 15 nM, respectively.

  • hBChE-IN-2

    hBChE-IN-2 is a butyrylcholinesterase (BChE) inhibitor and cannabinoid receptor 2 (CB2R) agonist with neuroprotective activity for the study of Alzheimer's disease-like neurological disorders.

  • CP-810123

    CP-810123 is a new alpha 7 nAChR agonist for the treatment of cognitive impairment associated with psychiatric or neurological disorders such as schizophrenia and Alzheimer's disease.